Clinical Trial Update: Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis [Phase 3]

View source ↗

Summary

ACADIA's ACP-204 is being evaluated in a Phase 3 open-label extension trial for Lewy body dementia with psychosis, with enrollment by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lewy Body Dementia

Drugs mentioned

• ACP-204

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Lewy Body Dementia Psychosis | Phase 3 | Status: ENROLLING_BY_INVITATION